FdaApplication
BLA 125521
Identifiers
- fda_app_no: BLA125521
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2016-03-22 |
Revenue by product
TALTZ
| Period | Revenue |
|---|---|
| Q2 2026 | $856.0M |
| Q1 2026 | $732.0M |
| Q4 2025 | $1.1B |
| Q3 2025 | $901.5M |
| Q2 2025 | $847.6M |
| Q1 2025 | $761.9M |
| Q4 2024 | $1.9B |
| Q3 2024 | $1.8B |
| Q2 2024 | $1.6B |
| Q1 2024 | $1.2B |
| Q4 2023 | $784.6M |
| Q3 2023 | $744.2M |
| Q2 2023 | $703.9M |
| Q1 2023 | $527.0M |
| Q4 2022 | $707.8M |
| Q3 2022 | $679.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
TALTZ
| Period | Revenue |
|---|---|
| Q2 2026 | $856.0M |
| Q1 2026 | $732.0M |
| Q4 2025 | $1.1B |
| Q3 2025 | $901.5M |
| Q2 2025 | $847.6M |
| Q1 2025 | $761.9M |
| Q4 2024 | $1.9B |
| Q3 2024 | $1.8B |
| Q2 2024 | $1.6B |
| Q1 2024 | $1.2B |
| Q4 2023 | $784.6M |
| Q3 2023 | $744.2M |
| Q2 2023 | $703.9M |
| Q1 2023 | $527.0M |
| Q4 2022 | $707.8M |
| Q3 2022 | $679.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TALTZ | IXEKIZUMAB | 80MG/ML | Injection |
| TALTZ | — | 80MG/ML | Injection |
| TALTZ | — | 20MG/0.25ML | Injection |
| TALTZ | — | 40MG/0.5ML | Injection |
4 products